cell transplantation

[Leukemia] Scientists analyzed 1781 adult Hodgkin lymphoma patients who relapsed between 2006 and 2017 after a first autologous-stem-cell- transplantation. The four-year overall survival (OS) after relapse continuously increased from 32% for patients relapsing in 2006–2008, to 63% for patients relapsing in 2015–201.7

[Bone Research] Scientists summarize the latest research progress on two aspects of spinal cord injury pathology: intraneuronal microenvironment imbalance and regenerative microenvironment imbalance.

[Annals of Hematology] Scientists evaluated the mutational profile of 19 lymphoma/myeloma patients, at both pre-autologous stem cell transplantation (pre-ASCT) and therapy-related myeloid neoplasm (t-MN) diagnosis, using a targeted NGS approach; 26 non-developing t-MN control patients were also studied pre-ASCT.

[International Journal of Hematology] Scientists investigated the optimal timing and cutoff value to ascertain the value of NPM1 mutation in measurable residual disease assessment.

[US FDA] The FDA approved axicabtagene ciloleucel for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

[Blood Cancer Journal] The authors focus on induction therapies prior to ASCT examining the latest data and guidelines on triplet and quadruplet regimens.